Evidence map›Paper›PMID 33114393›Full record

ReviewCancers2020

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer.

Elisa Gobbini, Aurélie Swalduz, Matteo Giaj Levra, Sandra Ortiz-Cuaran, Anne-Claire Toffart, Maurice Pérol, Denis Moro-Sibilot, Pierre Saintigny

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05236114 (TEMPUS GEMINI NSCLC STUDY), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05236114 recruitingnot on this mapstarted 2022, after this paper: background citation

TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)

TypeobservationalSponsorTempus AIRan2022 to 2029Enrolled1,200ConditionsNon-Small Cell Lung CancerArmsObservation
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  6. Recent Developments in Blood Biomarkers in Neuro-oncology.Current neurology and neuroscience reports · 2023
    Review
  7. Liquid biopsy for early detection of lung cancer.Chinese medical journal pulmonary and critical care medicine · 2023
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Current status of ctDNA in precision oncology for hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Elisa GobbiniThoracic Oncology Unit, CHU Grenoble-Alpes, Grenoble 38700, France.
Aurélie SwalduzDepartment of Medical Oncology, Centre Léon Bérard, Lyon 69373, France.
Matteo Giaj LevraThoracic Oncology Unit, CHU Grenoble-Alpes, Grenoble 38700, France.
Sandra Ortiz-CuaranUniv Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, France.
Anne-Claire ToffartThoracic Oncology Unit, CHU Grenoble-Alpes, Grenoble 38700, France.
Maurice PérolDepartment of Medical Oncology, Centre Léon Bérard, Lyon 69373, France.
Denis Moro-SibilotThoracic Oncology Unit, CHU Grenoble-Alpes, Grenoble 38700, France.
Pierre SaintignyUniv Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, France.
Centre Hospitalier Universitaire de Grenoble · FRUniversité Claude Bernard Lyon 1 · FRCentre Léon Bérard · FR

Funding

Integrated Cancer Research Site (SIRIC) LYriCAN Grant INCa INCa-DGOS-4664
6 · The paper itself

Abstract

Tumor genomic profiling has a dramatic impact on the selection of targeted treatment and for the identification of resistance mechanisms at the time of progression. Solid tissue biopsies are sometimes challenging, and liquid biopsies are used as a non-invasive alternative when tissue is limiting. The clinical relevance of tumor genotyping through analysis of ctDNA is now widely recognized at all steps of the clinical evaluation process in metastatic non-small cell lung cancer (NSCLC) patients. ctDNA analysis through liquid biopsy has recently gained increasing attention as well in the management of early and locally advanced, not oncogene-addicted, NSCLC. Its potential applications in early disease detection and the response evaluation to radical treatments are promising. The aim of this review is to summarize the landscape of liquid biopsies in clinical practice and also to provide an overview of the potential perspectives of development focusing on early detection and screening, the assessment of minimal residual disease, and its potential role in predicting response to immunotherapy. In addition to available studies demonstrating the clinical relevance of liquid biopsies, there is a need for standardization and well-designed clinical trials to demonstrate its clinical utility.

Indexed as

biomarkercirculating tumor DNAliquid biopsylung cancernext-generation sequencing

Identifiers

PMID33114393
PMCPMC7693855
OpenAlexW3094290269

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.